Dr. Janet Chollet

Dr. Janet A. Chollet is a board-certified obstetrician–gynecologist, biotech co-founder, and translational medicine leader based in Boston. She serves as the Co-Founder and Chief Medical Officer of Procyrn LLC, where she directs the development of sustained-release hydrogel immune therapeutics and reformulated antivirals. Her focus includes maternal–fetal health, neuroinflammation, and HPV-related cervical disease, all areas of urgent unmet medical need. Her career spans more than thirty years, bringing together clinical practice, teaching, research, and biotechnology. She has practiced at respected institutions, including Beth Israel Deaconess Medical Center and the University of Pittsburgh. Over the years, she has helped advance early-stage programs and secured three U.S. patents in women’s health drug delivery. Her path reflects a continuous effort to connect clinical observations with translational medicine. Dr. Janet Chollet earned her Bachelor of Science in Neuroscience from the University of California, Santa Barbara, in 1986. Driven by her interest in how science could translate into medical progress, she continued her education at New York Medical College, where she completed her Doctor of Medicine degree in 1991. From 1991 to 1995, she trained in Obstetrics and Gynecology at LAC/USC Women’s Hospital, a residency that shaped her lifelong commitment to advancing therapeutic care for women and families. Following residency, she joined Magee-Women’s Hospital, affiliated with the University of Pittsburgh, as a staff physician and instructor. Between 2000 and 2007, she cared for patients while mentoring young physicians. In 2007, she joined Beth Israel Deaconess Medical Center in Boston, where she continues to practice as an obstetrician–gynecologist and contribute to academic training. Her career in both patient care and translational research has remained deeply connected. In 2005, Janet Chollet co-founded Pear Tree Pharmaceuticals, a company dedicated to site-targeted therapies for women’s health. Pear Tree focused on new treatments for breast cancer survivors and women with vulvovaginal atrophy. Serving as Vice President of Clinical Affairs until 2018, she played a key role in developing vaginal delivery technologies that reduced systemic exposure while treating localized symptoms. Her contributions resulted in three patents: US 9,693,953 — Method of treating atrophic vaginitis US 9,675,546 — Method of treating atrophic vaginitis with triphenylethylene derivatives US 9,480,662 — Compositions and methods for topical tamoxifen citrate therapy This intellectual property was central to Pear Tree’s merger with Dare Bioscience (NASDAQ: DARE), a company advancing women’s health therapies. In 2023, Janet Chollet, MD, co-founded Procyrn LLC, a Boston-based biotechnology company. As Chief Medical Officer, she guides clinical development, translational strategy, and regulatory planning. Procyrn is advancing several therapeutic programs. The first, Maternal–Fetal Health (PC101), addresses preeclampsia and HELLP syndrome. This program uses a sustained-release hydrogel biologic to stabilize maternal–fetal health and reduce the need for preterm delivery. Preclinical validation has been completed, and development continues with Northeastern University and Charles River Laboratories. Her second program addresses Neuroinflammation and ALS. Collaborating with Jackson Laboratory, she is advancing immune-modulating strategies for C9orf72-associated amyotrophic lateral sclerosis, the most common genetic form of ALS. This initiative extends her translational focus beyond obstetrics and gynecology into neurodegenerative disease. Her third program targets HPV-Driven Cervical Dysplasia. Since current treatments rely mainly on excisional procedures with associated risks, this program works on a localized antiviral delivery system for the cervicovaginal environment. In vitro validation studies are underway with Charles River Laboratories. She is also exploring Autism Prevention Through Maternal–Fetal Immune Therapeutics. Based on emerging research linking maternal immune activation and placental inflammation to fetal neurodevelopment, this exploratory concept seeks to test pregnancy-compatible immune therapeutics that may reduce risk factors for autism. Though early, it reflects her broader vision of preventive maternal–fetal interventions. Beyond her scientific work, Dr. Chollet is experienced in regulatory planning and development execution. She emphasizes reproducibility, clear go/no-go criteria, and alignment between program milestones and funding cycles, ensuring that progress is disciplined and reliable. Earlier in her career, she co-wrote the Emmy-winning ER episode “Love’s Labor Lost,” which earned five awards. Although offered a staff writing role by Warner Bros., she chose to remain in medicine, underscoring her dedication to healthcare and revealing her creative voice. Dr. Janet Chollet values family, wellness, and creative exploration outside her professional responsibilities. She prioritizes exercise and strength training, enjoys time with family and pets, and finds focus in golf. Her interests include travel, writing, and discovery. Recently, she has also begun exploring artificial intelligence in clinical workflows and translational medicine, seeking to understand how technology can accelerate progress from research to patient care.